Results 81 to 90 of about 17,859 (212)

Integrating evidence for managing asthma in patients who smoke [PDF]

, 2014
Peer reviewedPublisher ...
Bjermer, Leif, Chisholm, Alison, Popov, Todor A, Price, David   +3 more
core   +1 more source

What Is Known About Asthma Care and Management for Children and Young People Under 18 Years of age in New Zealand. A Scoping Review

The Clinical Respiratory Journal, Volume 19, Issue 12, December 2025.
Children in Aotearoa New Zealand experience variable asthma care. This review reveals critical gaps in education, treatment adherence, and culturally safe services, disproportionately affecting Māori and Pacific children. Strengthening family/whānau‐centred and culturally responsive care is vital for improving outcomes.
J. Blamires, M. Foster, B. Kanengoni‐Nyatara   +2 more
wiley   +1 more source

Uncovering the regional localization of inhaled salmeterol retention in the lung

Drug Delivery, 2018
Treatment of respiratory disease with a drug delivered via inhalation is generally held as being beneficial as it provides direct access to the lung target site with a minimum systemic exposure.
Erica Bäckström, Gregory Hamm, Anna Nilsson, Britt-Marie Fihn, Nicole Strittmatter, Per Andrén, Richard J. A. Goodwin, Markus Fridén   +7 more
doaj   +1 more source

INFLUENCE OF BRONCHOLYTIC THERAPY ON VENTRICULAR RHYTHM DISORDERS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Рациональная фармакотерапия в кардиологии, 2016
Aim. To evaluate effects of broncholytic therapy on ventricular rhythm disorders and high resolution electrocardiogram indices in patients with chronic obstructive pulmonary disease (COPD).Material and methods.
Kh. Kh. Shugushev, M. V. Gurizheva, V. M. Vasilenko   +2 more
doaj   +1 more source

A transcriptome-driven analysis of epithelial brushings and bronchial biopsies to define asthma phenotypes in U-BIOPRED [PDF]

, 2016
RATIONALE AND OBJECTIVES: Asthma is a heterogeneous disease driven by diverse immunologic and inflammatory mechanisms. We used transcriptomic profiling of airway tissues to help define asthma phenotypes. METHODS: The transcriptome from bronchial biopsies
Adcock, IM, Auffray, C, Baribaud, F, Chanez, P, Chung, KF, Corfield, J, Dahlen, B, Dahlen, SE, De Meulder, B, Djukanovic, R, Fleming, L, Fowler, S, Guo, Y, Hoda, U, Howarth, P, Krug, N, Kuo, CS, Lefaudeux, D, Loza, M, Pandis, I, Pavlidis, S, Rossios, C, Rowe, A, Sandström, T, Shaw, D, Sousa, A, Sterk, PJ, U-BIOPRED Project Team, Wilson, SJ   +28 more
core   +4 more sources

Prognostic utility of pre‐biologic treatment correlates of childhood severe asthma exacerbation risk: Real world evidence

Pediatric Allergy and Immunology, Volume 36, Issue 12, December 2025.
Abstract Background Biologics have been shown to substantially reduce the risk of severe asthma exacerbations (SAEs) among children with moderate or severe asthma; however, not all eligible patients who initiate biologic treatment experience a reduced risk of SAEs.
Arthur H. Owora, Bowen Jiang, Yash Shah, Benjamin Gaston, Erick Forno   +4 more
wiley   +1 more source

The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study

International Journal of COPD, 2017
Rupert Jones,1 Jessica Martin,2 Vicky Thomas,3 Derek Skinner,4 Jonathan Marshall,5 Martina Stagno d’Alcontres,2 David Price2,6 1Clinical Trials and Health Research, Institute of Translational and Stratified Medicine, Plymouth University Peninsula ...
Jones R, Martin J, Thomas V, Skinner D, Marshall J, Stagno d'Alcontres M, Price D   +6 more
doaj  

Prediction of disease progression, treatment response and dropout in chronic obstructive pulmonary disease (COPD). [PDF]

, 2014
Drug development in chronic obstructive pulmonary disease (COPD) has been characterised by unacceptably high failure rates. In addition to the poor sensitivity in forced expiratory volume in one second (FEV1), numerous causes are known to contribute to ...
Danhof, M, Della Pasqua, O, Facius, A, Maas, HJ, Musuamba, FT, Teutonico, D, Yang, S   +6 more
core   +1 more source

Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma [PDF]

, 2010
Background Formoterol is a long-acting beta(2)-agonist but because it has a fast onset of action it can also be used as a relief medication. Objectives To asses the efficacy and safety of formoterol as reliever therapy in comparison to short-acting ...
Cates, CJ, Welsh, EJ
core   +1 more source

Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study [PDF]

, 2012
Introduction: The inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting beta2-agonist, formoterol fumarate (formoterol), have been combined in a single aerosol inhaler (fluticasone/formoterol).
Aalbers, René, Bodzenta-Lukaszyk, Anna, Brusselle, Guy, Grothe, Birgit, McIver, Tammy   +4 more
core   +1 more source